These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12202679)

  • 1. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
    Winquist E; Bramwell V; Vandenberg T
    J Clin Oncol; 2002 Sep; 20(17):3748-9; author reply 3749-50. PubMed ID: 12202679
    [No Abstract]   [Full Text] [Related]  

  • 2. Anastrozole versus progestins/tamoxifen.
    Beat T
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S49-51. PubMed ID: 12409073
    [No Abstract]   [Full Text] [Related]  

  • 3. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Copur MS; Ledakis P; Bolton M; Norvell M; Muhvic J
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331343
    [No Abstract]   [Full Text] [Related]  

  • 4. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Costa SD; Kaufmann M
    J Clin Oncol; 2001 May; 19(9):2580; author reply 2580-2. PubMed ID: 11331346
    [No Abstract]   [Full Text] [Related]  

  • 5. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Tonkin K
    J Clin Oncol; 2001 May; 19(9):2579-80; author reply 2580-2. PubMed ID: 11331344
    [No Abstract]   [Full Text] [Related]  

  • 6. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Bagley CM; Rowbotham RK
    J Clin Oncol; 2001 May; 19(9):2578-9; author reply 2580-2. PubMed ID: 11331342
    [No Abstract]   [Full Text] [Related]  

  • 7. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Panasci LC
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
    [No Abstract]   [Full Text] [Related]  

  • 8. Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
    Mouridsen HT; Chaudri-Ross HA
    Eur J Cancer; 2004 May; 40(7):1095-6; author reply 1097. PubMed ID: 15093587
    [No Abstract]   [Full Text] [Related]  

  • 9. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 11. World's largest breast cancer treatment trial supports anastrozole use.
    Oncology (Williston Park); 2002 Jan; 16(1):63. PubMed ID: 11831610
    [No Abstract]   [Full Text] [Related]  

  • 12. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
    Yang Y; Pan W; Tang X; Wu S; Sun X
    Oncotarget; 2017 Jul; 8(29):48362-48374. PubMed ID: 28415634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors continue their ATAC on tamoxifen.
    Nicholls H
    Trends Mol Med; 2002; 8(4 Suppl):S12-3. PubMed ID: 11927281
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocrine options for breast cancer treatment: looking beyond tamoxifen.
    Watanabe T; Sonoo H
    Breast Cancer; 2000; 7(4):345-9. PubMed ID: 11114863
    [No Abstract]   [Full Text] [Related]  

  • 15. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Woods B; Veenstra D; Hawkins N
    Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New findings about endocrine therapy for breast cancer.
    Davidson NE; Visvanathan K; Emens L
    Breast; 2003 Dec; 12(6):368-72. PubMed ID: 14659107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
    Buzdar AU
    J Clin Oncol; 2004 Aug; 22(15):3199-200; author reply 3200-1. PubMed ID: 15284276
    [No Abstract]   [Full Text] [Related]  

  • 18. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
    Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in cancer: what makes for a successful study?
    Tobias JS; Baum M; Thornton H
    Ann Oncol; 2000 Nov; 11(11):1371-3. PubMed ID: 11142473
    [No Abstract]   [Full Text] [Related]  

  • 20. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
    Wu K; Brown P
    J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.